Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
The key phrase in the subhead excerpted above is “upfront treatment.“ Pre-habilitation is a type of upfront treatment. According to the study linked below, upfront treatment is not an autologous stem cell transplant (ASCT). Upfront treatment is not maintanence therapy. The term upfront treatment for newly diagnosed multiple myeloma patients is induction therapy or the initial therapy for newly diagnosed MM patients.
According to the first study linked below, newly diagnosed MM patients who achieve MRD – status after induction therapy have longer remissions as well as longer overall survival aka length of life.
The question then, is how to achieve MRD- status in upfront therapy? While no one can guarantee that any newly diagnosed MM patient can achieve MRD- status, I can cite evidence-based MM therapies that show increases in chemo efficacy. Pre-habilitation is one such therapy.
The second and third studies linked below cite probiotics and pre-habilitation as non-conventional therapies that can increase a MM patient’s chance of reaching MRD- status after “upfront therapy.”
Are you a newly diagnosed multiple myeloma patient? To learn more about evidence-based, non-toxic therapies to manage your MM, scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there,
“Importance- Numerous studies have evaluated the prognostic value of minimal residual disease (MRD) in multiple myeloma (MM). Most studies were small and varied in terms of patient population, treatment, and MRD assessment methods.
Study Selection-Eligible studies reported MRD status and progression-free survival (PFS) or overall survival (OS) in ≥ 20 patients following treatment. Among 405 articles identified, 21 met the initial eligibility criteria and were included in the analysis…
Results-Fourteen studies (n = 1,273) provided data on the impact of MRD on PFS, and 12 studies (n = 1,100) on OS. Results were reported specifically in patients who had achieved conventional complete response (CR) in 5 studies for PFS (n = 574) and 6 studies for OS (n = 616).
MRD-negative status was associated with significantly better PFS overall and in studies specifically looking at CR patients. OS was also favorable in MRD-negative patients overall and in CR patients Tests of heterogeneity found no significant differences among the studies for PFS and OS.
Conclusions and Relevance- MRD-negative status after treatment for newly diagnosed MM is associated with long-term survival. These findings provide quantitative evidence to support the integration of MRD assessment as an endpoint in clinical trials of MM.”
“Abstract- Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity after upfront treatment have superior outcomes compared with those who remain MRD+. Recently, associations have been shown between specific commensal microbes and development of plasma cell disorders. Here, we report the association between intestinal microbiota composition and treatment outcome in MM…
“Many of the early studies on cancer prehabilitation typically focused exclusively on building strength and stamina through an appropriate exercise regimen; however, more recent research has supported a multimodal approach that encompasses more than one intervention (ie, a combination of exercise, nutrition, and psychological strategies) to better prepare patients for the challenges associated with upcoming cancer treatments.2..”